These include mutant HER2 for predicting response to neratinib in metastatic breast cancer [76,77], mutant AKT1 for predicting response to capivasertib, also in breast cancer [77], and tumour mutational burden for predicting response to immune checkpoint-based immunotherapy in advanced NSCLC [78,79,80]. Here, ERBB2 is linked to breast cancer.